Lecap Asset Management Ltd. Purchases New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Lecap Asset Management Ltd. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,709 shares of the biopharmaceutical company's stock, valued at approximately $461,000.

A number of other hedge funds have also recently made changes to their positions in the business. Brighton Jones LLC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $243,000. Truist Financial Corp increased its holdings in Alnylam Pharmaceuticals by 136.6% during the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock valued at $1,035,000 after purchasing an additional 2,539 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $1,063,000. IFP Advisors Inc grew its position in shares of Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 47 shares during the last quarter. Finally, Amalgamated Bank raised its holdings in shares of Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Amalgamated Bank now owns 8,484 shares of the biopharmaceutical company's stock valued at $1,996,000 after acquiring an additional 205 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ALNY shares. Bank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, March 21st. HC Wainwright restated a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Scotiabank increased their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 31st. Royal Bank Of Canada lifted their price target on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research report on Friday, March 21st. Finally, Chardan Capital raised their price objective on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty have issued a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $340.00.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the sale, the chief executive officer directly owned 48,948 shares of the company's stock, valued at approximately $14,899,281.72. This trade represents a 39.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Trading Up 1.0%

ALNY traded up $3.26 on Monday, hitting $326.09. The company had a trading volume of 943,507 shares, compared to its average volume of 859,514. The business's fifty day simple moving average is $288.10 and its 200 day simple moving average is $264.02. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $327.21. The company has a market cap of $42.52 billion, a PE ratio of -156.02 and a beta of 0.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. During the same quarter last year, the firm posted ($0.16) EPS. Alnylam Pharmaceuticals's revenue for the quarter was up 20.2% compared to the same quarter last year. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.